spacer
home > ebr > winter 2018 > keeping it clean
PUBLICATIONS
European Biopharmaceutical Review

Keeping It Clean

Advanced therapy medicinal products (ATMPs) are for human use, often in the field of regenerative medicine. They can be stratified into one of the following three categories of product: gene therapy; somatic cell therapy; and tissue engineering and regenerative medicine.

Figures 1 and 2 provide an overview of the distribution of ATMPs currently in development or on the market according to clinical application (1). The sponsors of ATMPs differ widely from the classical, heavily regulated, pharmaceutical market (see Figure 3). Currently, roughly 75% of ATMPs are being developed within the non-commercial sector (universities, hospitals, institutes and so forth) Ė an aspect that adds unique and significant regulatory challenges when guaranteeing that such products comply with the strict requirements for biological medicinal products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andy Bailey is a virologist who has been actively involved in the pathogen safety of biopharmaceuticals for over 20 years. Originally a biochemist, Andy served for nine years at the MRC virology unit in Glasgow, Scotland. In 1995, he moved as Director of virus validation services to Q-One Biotech, and later to the pathogen safety group of Baxter Healthcare in Vienna, Austria. Since 2005, Andy has been a founder and Chief Executive Officer of ViruSure in Vienna, Austria, a company specialising in virus and prion safety testing of biopharmaceutical products. Over the last 22 years, Andy has presented at numerous regulatory agencies, either in support of products or as an invited speaker at expert workshops.
spacer
Andy Bailey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinsonís Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinsonís disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. This latest extension includes grants from MJFF to support two projects:
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providersómaking the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement